San Francisco, CA - When a heart-failure patient has a defibrillator-equipped cardiac resynchronization therapy (CRT-D) device, antitachycardia pacing (ATP) is preferable to a shock for the treatment ...

It's dangerous in medicine to make decisions based solely on what makes intuitive sense. At the European Society of Cardiology (ESC) Congress 2023, we learned from the BUDAPEST CRT trial that the ...

AMSTERDAM, the Netherlands—Among patients with heart failure with reduced ejection fraction (HFrEF), a previously implanted pacemaker or ICD, and a significant RV pacing burden, upgrading to a cardiac ...

PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

AMSTERDAM -- A cardiac resynchronization therapy (CRT) upgrade produced solid clinical benefit for patients with pacing-induced heart failure with reduced ejection fraction (HFrEF), the small BUDAPEST ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

Most patients with a cardiac resynchronisation therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented for the ...

The ENDURALIFE battery technology (Boston Scientific) is designed to extend the battery life of Boston Scientific cardiac resynchronisation therapy-defibrillator (CRT‑D) devices. CRT‑Ds are a ...

Amsterdam, Netherlands – 26 Aug 2023: Upgrade to cardiac resynchronisation therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodelling ...

The company identified 7 studies that incorporated a cost-effectiveness analysis. It did not rely on these economic studies for its model, but the structure of the de novo model is similar to that ...